Research Analysts Set Expectations for XOMA Co.'s Q1 2024 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for XOMA in a note issued to investors on Monday, April 29th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings per share of ($0.85) for the quarter. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for XOMA's current full-year earnings is ($1.73) per share. Leerink Partnrs also issued estimates for XOMA's Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

Several other brokerages also recently issued reports on XOMA. SVB Leerink began coverage on shares of XOMA in a research note on Monday. They issued an "outperform" rating and a $40.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $74.00 price objective on shares of XOMA in a research note on Wednesday.

XOMA Stock Performance

XOMA stock traded down $0.38 during trading hours on Thursday, reaching $25.44. The stock had a trading volume of 13,491 shares, compared to its average volume of 20,276. The stock has a 50-day simple moving average of $25.06 and a 200 day simple moving average of $20.68. XOMA has a fifty-two week low of $13.48 and a fifty-two week high of $27.00. The stock has a market capitalization of $296.12 million, a PE ratio of -6.39 and a beta of 0.57. The company has a debt-to-equity ratio of 1.34, a current ratio of 8.68 and a quick ratio of 8.68.

XOMA (NASDAQ:XOMA - Get Free Report) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%.

Institutional Trading of XOMA

An institutional investor recently raised its position in XOMA stock. BNP Paribas Financial Markets raised its stake in XOMA Co. (NASDAQ:XOMA - Free Report) by 55.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,543 shares of the biotechnology company's stock after acquiring an additional 1,266 shares during the quarter. BNP Paribas Financial Markets' holdings in XOMA were worth $85,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.